Charmacy Pharmaceutical Co Ltd is a China-based company principally engaged in the distribution of pharmaceutical products. The Company mainly distributes western medicine, Chinese patent medicine and healthcare products to downstream distributors and retail terminals, while conducting dealings in the third-party logistics business of medicines and providing pharmaceutical products related consulting services. The Company's businesses cover the entire supply chain for pharmaceutical distribution, including procurement, sales, warehousing, transportation and delivery. The Company primarily operates its businesses in the domestic market.

Employees

827

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change
26-09-18	HK$5.495	0.00%
26-09-17	HK$5.495	0.00%
26-09-16	HK$5.495	0.00%
26-09-15	HK$5.495	0.00%
26-09-14	HK$5.495	0.00%

Delayed Quote Hong Kong S.E.

More quotes

Market Closed - Hong Kong S.E. 04:08:32 2026-09-18 EDT			5-day change	1st Jan Change
5.495 ^HKD	0.00%		0.00%	-24.62%

08-31	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-22	Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for Year Ended 31 December 2025, Payable on 25 June 2026	CI

Market Cap	507M 593M 75.64M 65.96M 62.28M 56.56M 106M 7.26B 106M 746M 288M 3.69B 284M 278M 11.87B	P/E 2024	18.7x	P/E 2025	15.3x
Enterprise Value	1.58B 1.85B 236M 206M 194M 176M 330M 22.62B 332M 2.32B 897M 11.5B 885M 866M 37B	EV / Sales 2024	0.41x	EV / Sales 2025	0.41x
Free-Float	25%	Yield 2024	4.89%	Yield 2025	4.58%

08-31	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-22	Charmacy Pharmaceutical Co., Ltd. Approves Final Dividend for Year Ended 31 December 2025, Payable on 25 June 2026	CI
03-27	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Charmacy Pharmaceutical Co., Ltd Announces Change of Company Secretaries, Effective March 27, 2026	CI
03-27	Charmacy Pharmaceutical Co., Ltd. Recommends Final Dividend for the Year Ended December 31, 2025, Payable on June 25, 2026	CI
12-12	Charmacy Pharmaceutical Co., Ltd. Approves Abolishment of the Board of Supervisors	CI
25-08-28	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-27	Charmacy Pharmaceutical Co., Ltd. Announces Change in Composition of the Nomination Committee, effective 27 June 2025	CI
25-03-28	Charmacy Pharmaceutical Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2024, Payable on 11 July 2025	CI
25-03-28	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-08-28	Charmacy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-05-20	Charmacy Pharmaceutical to Pay Final Dividend	MT
24-05-20	Charmacy Pharmaceutical Co., Ltd. Elects Ms. Zheng Xiyue as Employee Representative Supervisor of the Fourth Session of the Board of Supervisors	CI

21-10-17	Charmacy Pharmaceutical : EXCHANGE NOTICE - TRADING HALT	PU
21-04-27	Charmacy Pharmaceutical : FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD AT THE CONFERENCE ROOM ON 3RD FLOOR, NO. 235 SONG SHAN NORTH ROAD, LONGHU DISTRICT, SHANTOU CITY, GUANGDONG PROVINCE, THE PRC ON 31 MAY 2021 at 10 A.M. OR AT ANY ADJOURNMENT THEREOF	PU
21-03-26	Charmacy Pharmaceutical : (1) PROPOSED ELECTION OF DIRECTORS OF THE THIRD SESSION OF THE BOARD; AND (2) PROPOSED ELECTION OF SHAREHOLDER REPRESENTATIVE SUPERVISOR AND INDEPENDENT SUPERVISOR OF THE THIRD SESSION OF THE SUPERVISORY COMMITTEE	PU
21-03-12	Charmacy Pharmaceutical : CHANGE OF BUILDING NAME OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG	PU
19-12-05	FORM OF PROXY FOR USE AT THE 2020 FIRST H SHAREHOLDERS' CLASS MEETING TO BE HELD AT THE CONFERENCE ROOM ON 3RD FLOOR, NO. 235 SONG SHAN NORTH ROAD, LONGHU DISTRICT, SHANTOU CITY, GUANGDONG PROVINCE, THE PRC, ON 20 JANUARY 2020 AT 11:00A.M. OR ANY ADJOURNMENT THEREOF	PU

Charmacy Pharmaceutical Co., Ltd. Stock

Stocks

2289

CNE1000023D6

Pharmaceuticals

Valuation: Charmacy Pharmaceutical Co., Ltd.

Chart: Charmacy Pharmaceutical Co., Ltd.

Latest news: Charmacy Pharmaceutical Co., Ltd.

Press Releases: Charmacy Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Charmacy Pharmaceutical Co., Ltd.

Latest insider transactions

Pharmaceuticals Wholesale

Financials

Company Profile

Quotes

Current month	-0.09%
1 month	-0.09%
3 months	-12.78%
6 months	-5.26%
Current year	-24.62%

1 week	5.5	5.5
1 month	5.5	5.5
Current year	4.3	7.31
1 year	4.3	7.4
3 years	4.3	16.5
5 years	4.3	20
10 years	4.01	20

Manager	Title	Age	Since
Chuang Long Yao CEO	Chief Executive Officer	56	2015-04-30
Han Zi Zhang DFI	Director of Finance/CFO	47	2022-07-12
Yu Yan Zheng PRN	Corporate Officer/Principal	51	-

Director	Title	Age	Since
Chuang Long Yao CHM	Chairman	56	2015-04-30
Yu Yan Zheng BRD	Director/Board Member	51	2015-05-24
Chi Wai Wan BRD	Director/Board Member	50	2015-11-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/17/23	Chuang Long Yao	Other	Chief Executive Officer	9,720,000	9.0000%
6/29/22	Chuang Long Yao	Other	Chief Executive Officer	44,250,000	-
6/29/22	Chuang Long Yao	Other	Chief Executive Officer	44,250,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHARMACY PHARMACEUTICAL CO., LTD.	0.00%	0.00%	-8.87%	-57.60%	75.64M
MCKESSON CORPORATION	-0.56%	-0.78%	+26.74%	+104.70%	102B
CARDINAL HEALTH, INC.	-0.42%	-3.92%	+50.21%	+155.62%	52.42B
SIGMA HEALTHCARE LIMITED	+2.00%	-3.04%	-13.56%	+235.53%	20.85B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	-1.61%	-2.39%	-12.78%	-10.97%	7.88B
HUADONG MEDICINE CO., LTD	-0.19%	-0.61%	-38.37%	-36.77%	6.83B
H. LUNDBECK A/S	-0.19%	-4.19%	-4.96%	+15.34%	6.41B
SINOPHARM GROUP CO. LTD.	-0.07%	-2.21%	-19.07%	-31.26%	5.97B
GALENICA AG	-1.57%	-1.63%	-3.72%	+17.24%	4.94B
MEDIPAL HOLDINGS CORPORATION	-2.92%	+0.71%	+9.85%	+8.82%	3.79B
Average	-0.55%	-1.85%	-1.45%	+40.06%	21.11B
Weighted average by Cap.	-0.34%	-1.71%	+21.72%	+110.98%

	2024	2025
Net sales	4.44B 5.19B 662M 577M 545M 495M 927M 63.51B 931M 6.53B 2.52B 32.29B 2.49B 2.43B 104B	4.38B 5.13B 654M 571M 539M 489M 917M 62.78B 920M 6.45B 2.49B 31.92B 2.46B 2.4B 103B
Net income	53.28M 62.38M 7.95M 6.93M 6.55M 5.94M 11.14M 763M 11.18M 78.42M 30.26M 388M 29.87M 29.2M 1.25B	46.27M 54.17M 6.9M 6.02M 5.68M 5.16M 9.67M 663M 9.71M 68.1M 26.28M 337M 25.94M 25.36M 1.08B
Net Debt	836M 978M 125M 109M 103M 93.22M 175M 11.96B 175M 1.23B 475M 6.08B 468M 458M 19.57B	1.07B 1.26B 160M 140M 132M 120M 224M 15.36B 225M 1.58B 609M 7.81B 601M 588M 25.12B